avb6 integrin inhibitor + lysosomal degrader

in vitro degradation, Ph. I completed, discont.

derived from prior integrin inhibitors

J. Pharmacol. Exp. Ther., Jan. 26, 2021

GlaxoSmithKline, Stevenage, UK

Chemical structure of "compound 1" GSK αvβ6 integrin inhibitor (GSK 3008348)

The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a picomolar binder to αvβ6 with slow dissociation kinetics. The…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: